최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.29 no.3 = no.227, 2019년, pp.318 - 324
장호준 (계명대학교 의과대학 이비인후과) , 권택규 (계명대학교 의과대학 면역학교실) , 김동은 (계명대학교 의과대학 이비인후과)
Squamous cell carcinoma is the primary tumor type in head and neck cancers, the fifth most common malignant neoplasm world-wide. Survivin, a member of the inhibitor of apoptosis family, is highly expressed in head and neck carcinoma patients and correlated with more aggressive forms. In this study, ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Survivin은 언제 발현되는가? | Survivin은 inhibitor of apoptosis proteins (IAPs) family 중 하나로 배아기, 태아기 동안 발현 되나 다른 IAPs family와는 달리 정상 성인 조직에서는 발현되지 않으며 유방, 폐, 대장, 췌장, 두경부 영역의 악성종양에서 과발현되어 있다[1, 7, 27]. Survivin은 세포분열에도 중요한 역할을 할 뿐 아니라 암세포의 다양한 caspase의 활성화를 제한함으로써 apoptosis의 과정 또한 억제한다[24, 28]. | |
전세계에서 발병률이 여섯 번째로 높은 암은 무엇인가? | 두경부암은 전세계에서 발병률이 여섯 번째로 높은 암으로 그동안 수술적 치료를 선호하였으나 광범위한 절제에 따른 기능적 장애로 인해 항암치료에 대한 관심이 높아지고 있다. 두경부암에서 cisplatin이 가장 많이 사용되는 항암제이나 cisplatin 내성이 문제가 되고 있다. | |
2013년 보고된 한국의 두경부암의 유병률은 몇 명인가? | 두경부암은 전세계에서 연간 60만명이 진단되며 발병률이 여섯 번째로 높은 암이다[24, 25]. 한국에서 10만명당 50.9명의 유병률이 2013년에 보고되었다[8]. 일차적인 치료로 그 동안 수술적 치료를 선호하였으나 광범위 절제에 따른 음성장애, 연하장애와 같은 기능적 장애로 인해 항암치료에 대한 관심이 높아지고 있다[19]. |
Altieri, D. C. 2003. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54.
Ambrosini, G., Adida, C. and Altieri, D. C. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921.
Asechi, H., Hatano, E., Nitta, T., Tada, M., Iwaisako, K., Tamaki, N., Nagata, H., Narita, M., Yanagida, A., Ikai, I. and Uemoto, S. 2010. Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int. J. Oncol. 37, 89-96.
Burri, R. J. and Lee, N. Y. 2009. Concurrent chemotherapy and radiotherapy for head and neck cancer. Expert Rev. Anticancer Ther. 9, 293-302.
Chandele, A., Prasad, V., Jagtap, J. C., Shukla, R. and Shastry, P. R. 2004. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6, 29-40.
Colnaghi, R., Connell, C. M., Barrett, R. M. and Wheatley, S. P. 2006. Separating the antiapoptotic and mitotic roles of survivin. J. Biol. Chem. 281, 33450-33456.
Duffy, M. J., O'Donovan, N., Brennan, D. J., Gallagher, W. M. and Ryan, B. M. 2007. Survivin: a promising tumor biomarker. Cancer Lett. 249, 49-60.
Jung, K. W., Won, Y. J., Kong, H. J., Oh, C. M., Cho, H., Lee, D. H. and Lee, K. H. 2015. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res. Treat. 47, 127-141.
Kalavrezos, N. and Bhandari, R. 2010. Current trends and future perspectives in the surgical management of oral cancer. Oral Oncol. 46, 429-432.
Kita, A., Nakahara, T., Yamanaka, K., Nakano, K., Nakata, M., Mori, M., Kaneko, N., Koutoku, H., Izumisawa, N. and Sasamata, M. 2011. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk. Res. 35, 787-792.
Leverkus, M., Neumann, M., Mengling, T., Rauch, C. T., Brocker, E. B., Krammer, P. H. and Walczak, H. 2000. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 60, 553-559.
Lo Muzio, L., Pannone, G., Staibano, S., Mignogna, M. D., Rubini, C., Mariggio, M. A., Procaccini, M., Ferrari, F., De Rosa, G. and Altieri, D. C. 2003. Survivin expression in oral squamous cell carcinoma. Br. J. Cancer 89, 2244-2248.
Marioni, G., Bertolin, A., Giacomelli, L., Marchese-Ragona, R., Savastano, M., Calgaro, N., Marino, F., De Filippis, C. and Staffieri, A. 2006. Expression of the apoptosis inhibitor protein survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res. 26, 3813-3817.
Marur, S. and Forastiere, A. A. 2008. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin. Proc. 83, 489-501.
Molin, Y. and Fayette, J. 2011. Current chemotherapies for recurrent/metastatic head and neck cancer. Anticancer Drugs 22, 621-625.
Morgillo, F., Martinelli, E., Troiani, T., Orditura, M., De Vita, F. and Ciardiello, F. 2011. Antitumor activity of Sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine. Kinase Inhibitors. PLoS One 6, e28841.
Nakahara, T., Kita, A., Yamanaka, K., Mori, M., Amino, N., Takeuchi, M., Tominaga, F., Hatakeyama, S., Kinoyama, I., Matsuhisa, A., Kudoh, M. and Sasamata, M. 2007. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormonerefractory prostate tumor xenografts. Cancer Res. 67, 8014-8021.
Nakahara, T., Yamanaka, K., Hatakeyama, S., Kita, A., Takeuchi, M., Kinoyama, I., Matsuhisa, A., Nakano, K., Shishido, T., Koutoku, H. and Sasamata, M. 2011. YM155, a novel Survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 22, 454-462.
Nwizu, T., Ghi, M. G., Cohen, E. E. and Paccagnella, A. 2012. The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. Semin. Radiat. Oncol. 22, 198-206.
Peng, X. H., Karna, P., Cao, Z., Jiang, B. H., Zhou, M. and Yang, L. 2006. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem. 281, 25903-25914.
Pizem, J., Cor, A. and Gale, N. 2004. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 45, 180-186.
Sarela, A. I., Macadam, R. C., Farmery, S. M., Markham, A. F. and Guillou, P. J. 2000. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46, 645-650.
Seto, M., Jaeger, U., Hockett, R. D., Graninger, W., Bennett, S., Goldman, P. and Korsmeyer, S. J. 1988. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 7, 123-131.
Shin, S., Sung, B. J., Cho, Y. S., Kim, H. J., Ha, N. C., Hwang, J. I., Chung, C. W., Jung, Y. K. and Oh, B. H. 2001. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40, 1117-1123.
Siegel, R., Naishadham, D. and Jemal, A. 2012. Cancer statistics. CA. Cancer J. Clin. 62, 10-29.
Simard, E. P., Torre, L. A. and Jemal, A. 2014. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 50, 387-403.
Su, L., Wang, Y., Xiao, M., Lin, Y. and Yu, L. 2010. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg. Oral Med. Oral. Pathol. Oral Radiol. Endod. 110, 484-491.
Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
Tirro, E., Consoli, M. L., Massimino, M., Manzella, L., Frasca, F., Sciacca, L., Vicari, L., Stassi, G., Messina, L., Messina, A. and Vigneri, P. 2006. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 66, 4263-4272.
Yamanaka, K., Nakahara, T., Yamauchi, T., Kita, A., Takeuchi, M., Kiyonaga, F., Kaneko, N. and Sasamata, M. 2011. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin. Cancer Res. 17, 5423-5431.
Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., Pilotti, S., Zunino, F. and Daidone, M. G. 2002. Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell. Mol. Life Sci. 59,1406-1412.
Zhong, Q., Gao, W., Du, F. and Wang, X. 2005. Mule/ARFBP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095.
Zhu, L., Fukuda, S., Cordis, G., Das, D. K. and Maulik, N. 2001. Anti-apoptotic protein suvivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett. 508, 369-374.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.